Virginie Cérec

Abstract ND08: Discovery and development of a CD30 dual-payload ADC that combines MTI and Top1i to overcome drug resistance

Megan Rice, Francesca Casano, Wenting Zhang, Pan Pan et autres

Abstract Since the 1960s combination therapy has been practiced to address drug resistance in cancer patients. Initially utilizing multiple chemotherapeutic agents, approaches have evolved to include chemotherapeutics combined with a biologic or, more recently, multi-biologic regimens. Despite the potential of delivering multiple …

us, gb (code pays fourni par la source)

844 | PRIMAVERA: A PHASE I/II STUDY TO EVALUATE SAFETY AND EFFICACY OF THE PRMT5 INHIBITOR AZD3470 IN PARTICIPANTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES

Enrico Derenzini, Juan Pablo Alderuccio, Peter Borchmann, Herv Ghesquieres et autres

clinical benefit rate (stable disease or better) via Simon's minimax two-stage design.Exploratory endpoints include assessment of effect of tafasitamab on blood-brain barrier permeability, correlation of the relationships between tumor response and mutational profile, change in CSF cytokines including IL-10 during treatment, and …

it, us, de, fr, es, kr, au, gb, se, ca (code pays fourni par la source)

Safety and Preliminary Efficacy of Sabestomig (AZD7789), an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-(L)1 Therapy

Matthew Genyeh Mei, Gaetano Corazzelli, Frank Morschhauser, Elizabeth H. Phillips et autres

Background Immunotherapies targeting the PD-1/PD-L1 pathway have been shown to induce high response rates in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). However, most responses are partial and not durable. T cell immunoglobulin and mucin domain-containing protein-3 (TIM-3) is implicated as …

us, in, it, fr, gb, ca, dk, es, au (code pays fourni par la source)

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

Lydia S.H. Lee, Wen Chean Lim, Daria Galas‐Filipowicz, Kent T.M. Fung et autres

BACKGROUND: We used a proliferating ligand (APRIL) to construct a ligand-based third generation chimeric antigen receptor (CAR) able to target two myeloma antigens, B-cell maturation antigen (BCMA) and transmembrane activator and CAML interactor. METHODS: CARs in a 3+3 escalation design. RESULTS: The …

gb, nl (code pays fourni par la source)

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

Sven de Vos, Patrick Michael Reagan, Manish R. Patel, Nakhle S. Saba et autres

Background: R/R DLBCL patients (pts) who fail multiple lines of treatment or are ineligible for novel treatments, including CAR T-cell therapy, have poor clinical outcomes. The combination of the anti-CD47 monoclonal antibody (mAb) magrolimab and rituximab enhances macrophage-mediated antibody-dependent cellular phagocytosis in …

us, gb (code pays fourni par la source)

Transcriptional and Epigenetic Consequences of DMSO Treatment on HepaRG Cells

Hélène Dubois‐Pot‐Schneider, Caroline Aninat, Kathrin Kattler, Karim Fekir et autres

Dimethyl sulfoxide (DMSO) is used to sustain or favor hepatocyte differentiation in vitro. Thus, DMSO is used in the differentiation protocol of the HepaRG cells that present the closest drug-metabolizing enzyme activities to primary human hepatocytes in culture. The aim of our …

fr, de, jp (code pays fourni par la source)

Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process

Abigail Culshaw, Frederick Arce Vargas, Gerardo Santiago Toledo, Claire Roddie et autres

Abstract INTRODUCTION We have previously described AUTO1, a CD19 CAR with a fast off-rate binding domain, designed to reduce CAR T-cell immune toxicity and improve engraftment. Clinical testing in two academic studies in relapsed/refractory (r/r) paediatric [NCT02443831; CARPALL] and adult B-ALL, B-NHL …

gb, us (code pays fourni par la source)

Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Sonja Zweegman, Jim Cavet, Kwee Yong et autres

Introduction: Chimeric antigen receptor (CAR) T cell therapies directed against B cell maturation antigen (BCMA) have shown significant activity in patients with RRMM, however single antigen targeting with CAR-T cells can result in antigen negative relapse. Dual antigen targeting increases targetable tumor …

gb, nl (code pays fourni par la source)

A phase I study of pembrolizumab in combination with enadenotucirev (EnAd) (SPICE) in subjects with metastatic or advanced carcinoma.

Wael A. Harb, Virginie Cérec, Hilary McElwaine-Johnn, BRIAN R. CHAMPION et autres

TPS3112 Background: EnAd is a tumor-selective chimeric Ad11/Ad3 group B oncolytic adenovirus developed using a process of directed evolution. Phase I clinical studies have identified a well-tolerated dose and regimen for EnAd monotherapy. EnAd shows a high level of selective replication and …

us, gb (code pays fourni par la source)

Combination of photodynamic therapy and notch signaling pathway inhibition in the treatment of pancreatic cancer

Virginie Cérec, Tayyaba Hassan, Stephen P. Pereira

gb, us (code pays fourni par la source)

Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma

Michael Huw Chapman, Robert Tidswell, James Stephen Gerard Dooley, Neomal S. Sandanayake et autres

gb (code pays fourni par la source)

CYP4F3B Expression Is Associated with Differentiation of HepaRG Human Hepatocytes and Unaffected by Fatty Acid Overload

Stéphanie Madec, Virginie Cérec, Emmanuelle Plée‐Gautier, Joseph Antoun et autres

fr (code pays fourni par la source)